Clinical trial
Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure
NCT00063687 · Advanz Pharma, Industry · Completed
Key facts
| NCT number | NCT00063687 |
|---|---|
| Title | Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure |
| Official title | A Phase II-III Prospective, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oxypurinol Added to Standard Therapy in Patients With NYHA Class III-IV Congestive Heart Failure |
| Lead sponsor | Advanz Pharma, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Congestive Heart Failure |
| Intervention type | Drug |
| Interventions | Oxypurinol |
| Enrollment | 400 |
| Start date | Mar 1, 2003 |
| Completion | Jun 1, 2005 |
| First posted | Jul 3, 2003 |
| Last update posted | Aug 5, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: